NRX Pharmaceuticals Share Price Today

NRx Pharmaceuticals Q3FY26 Results: Earnings call set for November 17, 2026

NRx Pharmaceuticals will report Q3 2026 financial results on November 17, 2026. Conference call scheduled for 8:00 am ET on the same day. Secured $11.25 million DARPA contract in October 2026 for NRX-101 phase 3 trial. NRX-101 holds Breakthrough Therapy Designation for suicidal bipolar depression.

NRx Pharmaceuticals completes ketamine process validation, stockpiles supply

Completed three process validation lots of preservative-free ketamine under GMP conditions. Two-year stability data confirms no deterioration in purity, potency, or sterility. Commercially releasable drug supply is on hand pending ANDA approval. Milestone achieved ahead of November 10, 2026 FDA GDUFA goal date.

HOPE Therapeutics to deploy Zeta Surgical's FDA-cleared robotic TMS system

HOPE Therapeutics is the first interventional psychiatry network to deploy Zeta Surgical's FDA-cleared robotic TMS system. Clinical staff are completing orientation and training in Boston before deployment in Florida clinics. The AI-driven system adjusts TMS coils in real time with submillimeter precision. Deployment supports the SPARC-TMS trial for NRX-101 in partnership with Harvard McLean Hospital.

NRX Pharmaceuticals Q2 2026: EPS Misses, Cash Rises to $26.7 Million

NRX Pharmaceuticals reported a Q2 2026 EPS miss of $(0.44) against an estimate of $0.06, with sales of $1.101 million falling short of the $17.488 million forecast. The H1 2026 net loss improved to $18.0 million from $23.1 million in 2025, aided by the absence of non-recurring charges. Cash reserves rose to $26.7 million following a public offering, supporting operations for at least one year while the company advances its ketamine ANDA and NRX101 military trials.

NRx Pharma hosts call on FDA ketamine review progress

NRx Pharmaceuticals Inc announced a conference call on August 10, 2026, to discuss the FDA's completion of the first-cycle review of its ANDA for preservative-free intravenous ketamine. The FDA found no major deficiencies in the drug product but requested an attestation regarding the luer lock tip packaging. Industry statistics show only 14% to 18% of ANDAs are approved in the first cycle, making this milestone significant for de-risking commercialization.

NRx cites arbitration in Kadima acquisition dispute

NRx Pharmaceuticals responded to Kadima Neuropsychiatry Institute's allegations, citing a binding arbitration agreement due to Kadima's failure to meet closing conditions. The company argues the acquisition is immaterial to HOPE Therapeutics' business model and remains confident the dispute will be resolved equitably.